Conclusions. Taken together, these results showed that serum Gd-IgA1 and urinary IgA, IgG, IgM, NGAL, IL-1b, IL-6, IL-8, IL-10, IgA-IgG and IgA-sCD89 complexes were associated with nephritis in IgAV patients. Urinary IgA level may improve patient risk stratification for poor outcome.
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I N T R O D U C T I O N
Henoch-Schönlein purpura or IgA vasculitis (IgAV) is a systemic vasculitis affecting the small vessels of the skin and other organs, such as the kidneys. IgAV is common in children and less frequent in adults [1] . The long-term outcome of IgAV mainly depends on renal involvement [2] and nephritis occurs in 45-85% of adults [2] [3] [4] [5] .
The current markers used to assess IgAV inaccurately estimate the risk of nephritis occurrence and its long-term outcomes. Thus, clinicians have to use a suboptimal approach to guide therapeutic decisions. This issue has major consequences in the clinical management of IgAV patients. Undertreated patients may progress to chronic renal failure, while overtreated patients may experience serious adverse events from unnecessary, intensive therapeutic protocols. Identifying early biomarkers able to predict the course of the disease would clearly facilitate appropriate clinical decisions.
The pathophysiology of IgAV nephritis remains unclear, however, immune complex deposits are known to be involved [1] . Despite different clinical manifestations [6] , similarities with IgA nephropathy features, such as IgA deposits in the mesangium and abnormally glycosylated IgA1 [7] , suggest that common pathological mechanisms lead to kidney deposits in both diseases [5] . In IgA nephropathy, galactose-deficient IgA1 (Gd-IgA1) forms IgA-sCD89 complexes with the soluble Fc receptor CD89 [8, 9] and with autoantibodies such as IgG antiGd-IgA1 (IgA-IgG complexes) [10] . The levels of these circulating complexes correlate with disease progression [11, 12] and with the recurrence of IgA deposits after kidney transplantation [13] .
We hypothesized that cytokines, immunoglobulins, IgA complexes, IgA glycosylation and neutrophil gelatinaseassociated lipocalin (NGAL) could be involved in IgAV pathogenesis and may add to the prognostic value of conventional clinical risk factors. We conducted this prospective, multicentre study to assess the association of these biomarkers with renal involvement in an unselected population of patients with IgAV as their independent prognostic value.
M A T E R I A L S A N D M E T H O D S

Study design
This national, multicentre, prospective study [HSPrognosis study (NCT01610830)] was conducted in 19 hospitals in France between April 2010 and May 2015. The local ethical committee of Assistance Publique-Hôpitaux de Paris approved this study (number 10.649 bis) and informed, written consent was obtained from all the patients before any study-related procedure was performed. Patients were enrolled at the time of first skin rash appearance (Day 1). The inclusion criteria were a clinical diagnosis of IgAV, following the last European League Against Rheumatism/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society diagnostic criteria [14] and IgAV-positive skin biopsy results. The exclusion criteria were an absence of active IgA-V skin lesions, treatment with immunosuppressive drugs or steroids during the 2 weeks prior to skin rash appearance, thrombocytopenia an absence of consent and age <18 years.
For controls, blood and urine samples were collected at the time of a medical consultation for a scheduled surgery or a cognitive assessment in the gerontology unit.
On Day 1 (inclusion), the evaluation included taking each patient's medical history, performing a physical examination and collecting a skin biopsy specimen of a new purpuric lesion.
A renal biopsy was performed if indicated by clinical examination and biological tests, including haematuria and a proteinuria:creatininuria ratio >0.5 g/g and/or renal failure. All renal biopsies were independently examined by two pathologists in blind conditions. On immunofluorescence, the predominance of mesangial IgA among glomerular immunoglobulin deposits was examined. At least 10 glomeruli had to be present on the biopsy. We semi-quantitatively evaluated endocapillary lesions and their focal or diffuse distribution; extracapillary proliferation, graded according to the number of glomeruli involved, and interstitial fibrosis (area percentage). The proportions of glomeruli involved by crescents, fibrinoid necrosis and global sclerosis were also recorded. All biopsies were then classified according to the previously described criteria [2] : Class I, mesangiopathic glomerulonephritis; Class II, focal and segmental glomerulonephritis; Class III, endocapillary proliferative glomerulonephritis; Class IV, endocapillary and extracapillary glomerulonephritis; Class V, fibrotic kidney.
After 1 year (follow-up), the clinical and physical examination, including of any therapeutics used, were repeated.
Study outcomes
IgAV renal involvement. Renal involvement was defined as the presence of haematuria and/or a proteinuria:creatininuria ratio !0.5 g/g and/or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 [determined using the Modification of Diet in Renal Disease (MDRD) formula]. Kidney biopsies were performed when clinical presentation required further investigations.
Renal outcome. A poor outcome was defined as death, a proteinuria:creatininuria ratio >0.5 g/g or an eGFR decline, as described elsewhere [12] . Patients with an eGFR <30 mL/min/ 1.73 m 2 , with a decrease in eGFR >15 mL/min/1.73 m 2 when eGFR was <60 mL/min/1.73 m 2 at Day 1 or with a decrease in eGFR >30 mL/min/1.73 m 2 when eGFR was between 60 and 90 mL/min/1.73 m 2 at Day 1 were considered progressive patients.
Biomarker measurement in fluids
At Day 1, 85 blood samples and 83 urine samples from IgAV patients were available. Cytokine Binding Assay Kits (BD Biosciences, Le Pont de Claix, France) were used to determine the concentrations of interleukin (IL)-1b, IL-6, IL-8, IL-10, IL12p70 and tumour necrosis factor a (TNF-a) in plasma and urine, and bead fluorescence was analysed on a Canto II cytometer (BD Biosciences). NGAL concentration was determined using enzyme linked immunosorbent assay (ELISA) kits (BioPorto, Hellerup, Denmark). For immunoglobulins, the concentrations of IgA, IgM and IgG were determined in sera by nephelometry. The levels of IgD and IgE in sera and all immunoglobulin concentrations in urine were assessed by ELISA kits (Bethyl Laboratories, Montgomery, TX, USA). IgA1 glycosylation was evaluated by a lectin ELISA using Helix aspersa agglutinin (HAA; Sigma-Aldrich, St. Louis, MO, USA), as previously described [15] . The positive control (purified deglycosylated IgA1) corresponded to 100% binding. For the IgA complex measurements, the ELISA was performed as follows: coating with anti-IgA antibody (1/500) and with A3 anti-CD89 (5 mg/ mL) for IgA-IgG and IgA-sCD89, respectively, overnight at 4 C, followed by blocking for 8 h at 4 C. Polyethylene glycolprecipitated serum or urine samples were incubated overnight at 1/10. Revelation was performed using anti-IgG (1/5000; Southern Biotech, Birmingham, AL, USA) or anti-IgA (1/2000; BD Biosciences) coupled with alkaline phosphatase. The plates were read at 405 nm using an Infinite M200 microplate reader (Tecan, Manndorf, Switzerland).
CD89 expression on blood myeloid cells
Ethylenediaminetetraacetic acid-treated venous peripheral blood samples (50 mL) were labelled with antibodies (BD Biosciences) as follows: anti-CD11b coupled with Pacific Blue, anti-CD15 with allophycocyanin (APC), anti-CD14 with APC-H7, anti-CD89 with phycoerythrin (PE) or isotype-PE for 20 min at room temperature. Then, red blood cells were lysed using BD lysing solution (BD Biosciences) for 10 min and were washed twice with phosphate-buffered saline, 2% bovine serum albumin and 0.01% azide. The samples were analysed using a Canto II system (BD Biosciences).
Statistical analysis
Median [interquartile range (IQR)] values and frequencies are provided for the description of continuous and categorical variables, respectively. The median values and proportions were compared using Mann-Whitney and Fisher's exact tests, respectively. Spearman's rank correlation coefficient was used to assess the correlation between two continuous variables.
For prediction analyses, we first built the conventional model for poor outcome based on clinical factors using univariate and multivariate logistic regression. Significant risk factors were entered into a single multivariate model using backward stepwise elimination to define the conventional model. Calibration and goodness of fit were assessed by visual examination of a calibration plot and tested with the HosmerLemeshow test.
Second, candidate biomarkers were added to the conventional model in order to determine which biomarkers were associated with the outcome, independent of conventional factors.
Third, we used the logistic regression model area under the curves (AUCs), the continuous net reclassification improvement and the integrated discrimination improvement to assess the incremental value of markers on the conventional model to predict outcome [16, 17] .
All tests were two-sided and P-values < 0.05 were considered significant. All statistical analyses were performed with STATA 12.0 (StataCorp, College Station, TX, USA) and R version 3.1.3 (R Development Core Team, Vienna, Austria).
R E S U L T S
Population at inclusion (Day 1)
Among the 91 patients prospectively screened between 2010 and 2015, a total of 85 patients with diagnosed IgAV were enrolled and constituted the study population (Figure 1) . Twenty-five patients did not exhibit renal involvement [IgAVrelated without nephritis (IgAV-woN) group] and 60 patients exhibited nephritis [IgAV-related nephritis (IgAV-N) group]. The demographic and baseline disease characteristics are presented in Table 1 . The median age was 58 (IQR 42-70) years. Males represented 58.8% of patients. Thirty-five patients (41.2%) had hypertension, 20 (59%) were treated with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blocker (ARBs), started before IgAV was diagnosed. More HSP-N patients than HSP-woN patients suffered from Biomarkers of IgAV nephritis outcome hypertension (P < 0.01). A total of 10.6% of patients exhibited diabetes. The following patients exhibited comorbidities classically associated with IgA deposits: 11 patients had liver disease (6 had alcoholic cirrhosis, 2 had hepatitis B cirrhosis, 2 had hepatitis C cirrhosis and 1 had haemochromatosis), 1 suffered from Crohn's disease and 1 suffered from ankylosing spondylitis (see related diseases, Table 1 ). Renal involvement was diagnosed in 60 (70.6%) patients, with haematuria in 53 (88.3%) HSP-N patients and significant proteinuria levels (75.0% of HSP-N patients). The median proteinuria:creatininuria ratio was 0.97 (IQR 0.46-2.30) g/g. Renal failure was present in 40.0% of HSP-N patients. The median serum creatinine level was 88.0 (IQR 70.0-139.8) mmol/L in the HSP-N group, which was not significantly different from those of the control group. Forty-one patients among the 60 patients with renal involvement had a renal biopsy. The most frequent lesion in renal biopsies was focal and segmental glomerulonephritis (Class II, 56%). The histological score highly correlated with proteinuria (q ¼ 0.71, P < 0.0001, Supplementary data, Figure S1 ) and not with eGFR.
Biological markers at inclusion (Day 1)
Immunoglobulins. Among the circulating immunoglobulins tested, the IgA and IgE serum concentrations of all IgAV patients were higher than those of the controls (P < 0.0001 and P < 0.01, respectively), and higher in IgAV-N adult patients than in IgAV-woN adult patients (P < 0.05 and P < 0.01, respectively; Table 2 ).
In urine samples, IgD and IgE were not detected. IgA, IgG and IgM urinary concentrations were increased in IgAV-N patients compared with the controls (P < 0.0001) and with IgAV-woN patients (P < 0.0001; Table 2 ). The Igk:Igj ratio in urine samples was also increased for IgAV-N patients compared with the controls and IgAV-woN patients (P < 0.0001; Table 2 ). There were significant positive correlations between proteinuria and IgA, IgG and IgM urinary concentrations for IgAV-N patients (Table 3) .
Cytokines. The serum concentrations of the cytokines IL1b, IL-6 and IL-8 were higher in the IgAV-N group than in the controls and IgAV-woN patients (Table 2) , whereas IL-10, IL12p70 and TNF-a serum concentrations were similar among IgAV patients and the controls.
In urine, IL-1b, IL-6, IL-8 and IL-10 concentrations were significantly higher in IgAV-N patients than in the controls and IgAV-woN patients (P < 0.0001; Table 2 ). Only IL-8 concentrations in urine from adults were positively correlated with proteinuria and negatively correlated with eGFR (Table 3) .
NGAL. We next measured the levels of NGAL, an established biomarker of kidney injury. The NGAL concentration was increased in plasma of IgAV patients compared with the controls (P < 0.0001) and in the urine of IgAV-N patients compared with the controls and IgAV-woN patients (P < 0.0001; Table 2 ). Plasma NGAL concentration was negatively correlated with eGFR (Table 3) . Urinary NGAL was negatively correlated with eGFR in adults ( Table 3) .
Markers of IgA nephropathy. In IgA nephropathy, circulating IgA1 harbours a deficiency of galactose. IgA1 was more hypogalactosylated in IgAV-N patients than in the controls and IgAV-woN patients (see percentage HAA binding in Table 2 ), as previously described [18] , and did not correlate with proteinuria or eGFR.
The levels of circulating IgA complexes (IgA-sCD89 and IgA-IgG) were increased in all IgAV patients compared with the controls (P < 0.0001; Table 2), with no difference between IgAV-woN and IgAV-N patients. In urine samples, these complex levels were increased only in IgAV-N patients compared with the controls and IgAV-woN patients (P < 0.001; Table 2 ). The urinary IgA-sCD89 complex percentages in serum from IgAV-N adults were positively correlated with proteinuria and negatively correlated with eGFR ( Table 3 ). The IgA-IgG complex percentages in IgAV-N adult urine were positively correlated with proteinuria ( Table 3 ). The increase of circulating sCD89 in IgAV patients was associated with a significantly decreased expression of CD89 at the surface of circulating monocytes (P < 0.05; Table 2 ), indicating a putative shedding of CD89.
Population at follow-up (1 year) and outcome Two patients were lost to follow-up ( Figure 2 ). The median follow-up time for IgAV patients was 13.3 (IQR 12.2-17.4) months. Seven (11.9%) patients in the IgAV-N group died without receiving immunosuppressive drugs (Table 4 ). The causes of death were cardiopathy in three patients and sepsis in four patients. Extrarenal relapses were only cutaneous and not frequent, occurring in 16 (19.2%) patients. They were more prevalent in the IgAV-woN (50.0%) group than the IgAV-N group Figure 2) . Among the 28 patients with nephritis, haematuria was detected in 21 (75%) (persistent since J0 for 15 of them) and proteinuria >0.5 g/g was present in 11 (39.3%) ( (Table 4) . Among the 43 patients treated with renin-angiotensin system blockers during the study, 23 had hypertension and 20 were treated before the study for this indication. Twenty received the treatment only for significant proteinuria. Among the 16 patients treated with colchicine during the study, 2 received the treatment for gout and the others for recurrent cutaneous vasculitis. Thirty-five (41.2%) patients were treated with steroids, six of them for severe extrarenal vasculitis. Seven patients received other therapies, all of them for nephritis: two patients were treated with cyclophosphamide, three patients were treated with rituximab and two patients received azathioprine. The patient baseline characteristics according to each treatment are described in Supplementary data, Table S1 .
A total of 22 patients were classified with a poor renal outcome (Table 4) Table 5 ]. The histological score of kidney biopsies was equivalent in both groups (Supplementary data, Table S2 ). None of treatments was associated with the kidney outcome (Supplementary data, Table S3 ). Serum IgM concentrations were decreased in patients with poor outcome (Table 5) . Urinary IgA, IgG, IgM and IgA complex concentrations were increased at inclusion (Day 1) for patients with a poor 1-year outcome compared with patients with a good outcome as evaluated by NGAL concentration in plasma (Table 5 ).
Conventional determinants of poor outcome at the time of disease onset
To build the conventional model for poor outcome, we considered the usual determinants of renal prognosis in IgAV ( Table S4 ). The independent determinants of poor outcome in multivariate analysis were eGFR (P ¼ 0.04) and age (P ¼ 0.02), and they were included in the conventional model (Table 6 , multivariate analysis). Proteinuria was eliminated as a non-significant covariate. The conventional model for poor outcome showed good calibration (Supplementary data, Figure S2 ) and goodness of fit (P ¼ 0.85).
Determinants of poor outcome among the candidate biomarkers
Identification of relevant candidate biomarkers for outcome prediction. We performed univariate analyses in order to identify the candidate biomarkers assessed at Day 1 that were associated with 1-year poor outcome (Supplementary data, Table S5 ). The following candidate biomarkers were associated with poor outcome: serum IgG (P ¼ 0.036), serum IgM (P ¼ 0.041), urine IgA (P < 0.001), urine IgG (P ¼ 0.010), urine IgM (P ¼ 0.005), urine NGAL (P ¼ 0.031), urine IgAsCD89 complexes (P ¼ 0.041) and urine IgA-IgG complexes (P ¼ 0.002).
Relevant biomarkers for outcome prediction independent of conventional risk factors. To identify the candidate biomarkers associated with poor outcome independent of conventional risk factors, we integrated each of them into the conventional model (Table 7) . Only urine IgA was associated with poor outcome independent of conventional risk factors [adjusted OR 2.12 (95% CI 1.20-3.74), P ¼ 0.009], including proteinuria and kidney histological score (Supplementary data, Table 7 . Association between top candidate biomarkers assessed at inclusion (Day 1) and poor 1-year outcome adjusted for age and eGFR (n ¼ 83) Table S6 ). Urine IgA concentration showed good performance to discriminate the patients with poor outcome from the patients with good outcome at the time of IgAV onset, with an AUC of 0.86 (95% CI 0.76-0.95, P < 0.0001; Figure 3A ). On the basis of an optimum cut-off of 1.13 g/mmol, IgA urine showed a sensitivity of 76.2%, a specificity of 80.0%, a positive predictive value of 76.2% and a negative predictive value of 80.3% for poor outcome.
Additional value of urine IgA beyond conventional parameters for risk stratification of outcomes patients in the correct direction in the patients with poor outcome by predicting a greater risk of poor outcome than by conventional risk factors and it reclassified 36/60 (60.0%) patients in the correct direction in the patients with good outcome by predicting a lower risk of poor outcome.
Comparison of IgAV to other proteinuric patients
As the IgAV-N patients exhibited proteinuria, the increase of IgA in urine could be due to a passive passage of macromolecules. We compared IgAV-N patients with proteinuric patients suffering from minimal change disease (MCD) and diabetic nephropathy (DN). MCD patients and DN patients exhibited a median of proteinuria of 0.51 (IQR 0.1-2.1) and 0.8 (0.2-1.8) g/g, respectively, associated with a decrease of serum IgG and an increase of urine IgG excretion (Table 8 ). This excretion was massive in MCD and DN, equivalent to that of IgAV-N patients. Interestingly, urine IgA concentration was not increased in MCD and DN patients; supporting the fact that urine IgA is a specific marker of IgAV-N.
D I S C U S S I O N
IgAV is generally a benign disorder. Long-term IgAV prognosis is correlated with the severity of nephritis. The pathological analysis of renal biopsies is the gold standard for the diagnosis and assessment of disease activity; however, frequent assessment based on biopsy specimens is difficult. Therefore, simple and safe alternatives are desirable. Several studies have shown that hypertension, histological score, persisting proteinuria >1 g/day at 1 year and impaired renal function at the time of diagnosis in patients with IgAV-N are associated with a poor prognosis [5] .
Currently there are no validated noninvasive markers for risk stratification. Based on previous studies of IgA nephropathy, which is considered to be a similar disease, and based on current knowledge of IgAV, we attempted to identify biomarkers of disease activity in this multicentre prospective study based on a highly phenotyped cohort of IgAV patients.
The results of our research support the idea that IgA nephropathy and IgAV-N share the same pathophysiological mechanisms. An aberrant O-linked glycosylation of IgA1 (Gd-IgA1) molecules has been proposed to be the central pathogenic mechanism in IgAV-N and IgA nephropathy, leading to IgA1 deposition [7, 18] . We confirmed in our IgAV cohort that the increase in serum Gd-IgA1 level was only associated with nephritis. Moreover, it has been described that in IgA nephropathy, recognition of this IgA1 hinge region neo-epitope by IgA or IgG antibodies leads to the generation of circulating immune complexes [19] . Here, we found that the level of IgA-IgG complexes was increased in the circulation of all IgAV patients. In contrast, in urine, these complex levels were only increased in IgAV-N patients compared with those in IgAV-woN patients. Higher levels of serum Gd-IgA1 at the time of diagnosis have been shown to be independently associated with a greater risk for renal deterioration in IgA nephropathy patients [20] . The serum levels of Gd-IgA1-specific antibodies, together with the levels of Gd-IgA1, can not only differentiate IgA nephropathy from other glomerular diseases, but are also correlated with IgA nephropathy activity [12, 21] . In our IgAV cohort, poor renal outcome was not associated with the serum levels of Gd-IgA1 or IgA-IgG complexes.
In IgA nephropathy, the binding of IgA to the Fc receptor CD89 induces cleavage of the CD89 extracellular domain, resulting in the release of IgA-sCD89 complexes. These immune complexes are trapped in the mesangium by the transferrin receptor, with transglutaminase 2 (TG2) leading to mesangial activation [9] . IgA nephropathy patients with progressive disease had lower serum levels of IgA-sCD89 complexes than did patients with a good prognosis [22] , as did recurrent IgA nephropathy patients after grafting compared with nonrecurrent patients [23] . Low levels of urinary CD89 and TG2 have recently been found in patients with active IgA nephropathy/IgAV-N compared with patients in remission [24] . We found that the circulating IgAsCD89 complex level was increased in all IgAV patients and was associated with decreased expression of CD89 at the monocyte cell surface. IgAV-N patients exhibited a higher level of these complexes in their urine.
Concerning pro-inflammatory cytokines, we found elevated levels of IL-1b, IL-6 and IL-8 in the serum of patients with and without nephritis compared with the controls. Urine IL-6 and IL-8 concentrations distinguished IgAV with and without nephritis, as previously described [25] . Increased serum IL-6 has been associated with the acute phase of IgAV [26] .
NGAL is associated with tubular damage and predicts renal injury. In IgA nephropathy patients, two studies suggest that NGAL could serve as a potential predictor for progression [27, 28] . In IgAV patients, urinary NGAL seems to distinguish IgAV patients with and without nephritis [29, 30] . We confirmed these results by showing that increased urinary NGAL was characteristic of IgAV-N.
Our study showed for the first time that urinary IgA concentration could improve the individual risk stratification of outcomes in IgAV beyond conventional clinical factors at the time of disease onset, which has direct consequences for patient care. The patients who are most likely to be at risk for disease progression could benefit from early care, monitoring and followup. A risk-stratified approach is greatly needed in the field of IgAV, where only a small proportion of patients will experience poor outcome and require an intensive therapeutic regimen. Moreover, urine IgA was a specific marker of IgAV-N and was not present in proteinuric MCD and DN patients. Future international prospective studies have to validate the use of this marker to predict poor kidney outcome in IgAV. Longer follow-up would also be desirable.
In conclusion, this large prospective cohort study furthers our understanding of the pathophysiology of IgAV, sharing the same mechanisms as IgA nephropathy. The serum levels of GdIgA1 and urinary levels of IgA, IgG, IgM, NGAL, IL-1b, IL-6, IL-8, IgA-IgG and IgA-sCD89 complexes were associated with IgAV nephritis at the time of diagnosis. Moreover, urine IgA improved patient risk stratification for poor outcome at disease onset beyond conventional clinical factors.
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